Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6742 in Systemic Lupus Erythematosus
NCT07515014Phase 2Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of e6742 in systemic lupus erythematosus (SLE) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: British Isles Lupus Assessment Group (BILAG) based Composite Lupus Assessment (BICLA) Response with Low Dose of Oral Corticosteroids (OCS) at 24 weeks. Started Mar 2026; status: recruiting.
02
Drugs
e6742
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07515014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07515014.